|
|
 |
 |
 |
 |
 |
|
FRIDAY,
29 SEPTEMBER 2006
Integrins in Cancer: Novel Therapeutic
Approaches
A
Satellite Symposium at the 31st Congress of the European Society
for Medical Oncology
Istanbul, Turkey
15:00 – 17:45
Chair:
John M. Kirkwood, MD
University of Pittsburgh Cancer Center
Pittsburgh, Pennsylvania, United States
|
|
C O N F I R M E D F A C U L T Y |
 |
|
| Gary
Hudes, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
John
M. Kirkwood, MD
University of Pittsburgh Cancer Center
Pittsburgh, Pennsylvania,
United States |
Mark
Middleton, MD
Cancer Research UK
London, United Kingdom
Eric
Raymond, MD
Institut Gustave-Roussy
Villejuif, France |
Dwayne
Stupack, PhD
University of California San Diego
San Diego, California,
United States |
|
 |
|
S C I E N T I F I C A G E N D A |
|
|
Friday, 29 September 2006
15:00
Introduction
John M. Kirkwood, MD
15:10
The biology of integrins
Dwayne Stupack, PhD, University of California San Diego,
San Diego, California, United States
15:40
Integrins in melanoma
Mark Middleton, MD, Cancer Research, UK, London, United
Kingdom
16:10
Integrins in prostate cancer
Gary Hudes, MD, Fox Chase Cancer Center, Philadelphia,
Pennsylvania, United States
16:40
Integrins in colorectal cancer
Eric Raymond, MD, Institut Gustave-Roussy, Villejuif,
France
17:10
Discussion and Question/Answer
Moderator: John M. Kirkwood, MD
17:30
Future Directions of integrin therapy in cancer treatment
John M. Kirkwood, MD
17:45
Adjourn |
|
|
W H O S H O U L D A T T E N D ? |
|
|
| This
educational program is intended for medical oncologists,
surgical oncologists, researchers, and other healthcare
professionals interested in novel agents targeting integrins
for the management of solid tumors including melanoma,
colorectal, and prostate cancer. No special training other
than basic knowledge of oncology is necessary for successful
participation in this program. |
|
|
|
O B J E C T I V E S |
|
|
| After
successful completion of this activity, participants
should be able to:
-
Discuss the application of
targeted therapy and the potential for reducing
adverse events currently associated with treatment
delivery.
-
Describe the biology of cancer
progression, including the role of the integrin
alpha-v, beta 3 in metastasis and angiogenesis.
-
Analyze the data to support
the use of antiangiogenesis therapy in patients
with colorectal and prostate cancer and melanoma.
|
|
|
|
|
R E G I S T R A T I O N |
|
|
| Registration
is complementary to attendees of the 31st ESMO Congress.
Pre-registration is closed. Space is limited. |
|
|
|
G E N E R A L I N F O R M A T I O N |
|
|
| CONFERENCE
LOCATION
Istanbul
Convention & Exhibition Center (ICEC)
Hilton Conference Center
Concert Hall
34267, Harbiye, Istanbul - Turkey
Dolmabahçe Halls A+B
|
|
|
|
O R G A N I Z E R |
|
|
|
|
